中国患者奥沙利铂过敏反应文献分析

doi:10.19803/j.1672-8629.2020.11.11

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (11): 798-802.
DOI: 10.19803/j.1672-8629.2020.11.11

中国患者奥沙利铂过敏反应文献分析

李敏¹, 钟巧妮², 赵丽³, 兰露露¹, 刘东¹, 张程亮^1,*

¹华中科技大学同济医学院附属同济医院药学部,湖北武汉 430030;
²武汉大学中南医院药学部,湖北武汉 430071;
³湖北省药品（医疗器械）不良反应监测中心,湖北武汉 430071

收稿日期:2020-11-10 修回日期:2020-11-10 出版日期:2020-11-15 发布日期:2020-11-10
通讯作者: ^*张程亮,男,博士,副教授,药物流行病学。E-mail：clzhang@tjh.tjmu.edu.cn
作者简介:李敏,女,硕士,临床药学与药理学。
基金资助:
湖北省药品（医疗器械）不良反应监测中心课题（20160422）; 华中科技大学同济医学院研究型临床医师资助计划（5001540076）

Literature analysis of Oxaliplatin Allergic Reactions in Chinese patients

LI Min¹, ZHONG Qiaoni², ZHAO Li³, LAN Lulu¹, LIU Dong¹, ZHANG Chengliang^1,*

¹Department of Pharmacy, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei 430030, China;
²Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan Hubei 430071, China;
³Hubei Center for ADR/ADE Monitoring,Wuhan Hubei 430071,China

Received:2020-11-10 Revised:2020-11-10 Online:2020-11-15 Published:2020-11-10

摘要/Abstract

摘要： 目的搜集中国患者奥沙利铂（oxaliplatin,OXA）过敏反应的病例报道文献,总结其特点及规律,以提高OXA临床应用安全性。方法检索万方数据和中国知网等中文文献数据库中OXA过敏反应相关病例报道文献,从患者性别、年龄、化疗周期、过敏反应发生时间、给药剂量、临床表现、严重程度和转归等方面进行统计和分析,检索时间为1999年1月1日至2019年5月31日。结果共纳入OXA过敏反应102例报告,患者平均年龄53岁,男女比例为1.04:1。OXA过敏反应可发生在用药的任何周期,过敏反应发生时间主要集中在30 min内,可累及消化、心血管、呼吸等多个系统。文献报道的OXA过敏反应中Ⅲ级较多,所有病例在停药或治疗后均好转。结论过敏反应是OXA常见药品不良反应,可导致化疗中断,严重过敏反应甚至对患者生命安全造成威胁。临床医护人员应关注OXA的过敏反应,加强监测和防治工作,提高患者用药安全性。

关键词: 奥沙利铂, 药品不良反应, 过敏反应, 用药安全

Abstract: Objective To collect case reports on oxaliplatin (OXA)-induced allergic reactions in Chinese patients, summarize their characteristics and regularities, and improve the safety of OXA in clinical application. Methods Chinese literature databases including Wanfang and CNKI etc from January 1999 fo May 2019. were searched for case reports of OXA-induced allergic reactions. Data on gender, age, chemotherapy cycles, the time allergic reactions occurred, dosage, clinical manifestations, severity and outcomes of the patients was statistically analyzed. Results A total of 102 OXA allergic reactions were reported. The average age of patients was 53 years old and the male-female ratio was 1.04:1. OXA-induced allergic reactions can occur in any cycle of medication, mostly within 30min, which can involve multiple systems such as digestive, cardiovascular and respiratory systems. Most of these allergic reactions are grade III, and all of these cases have improved after drug withdrawal or treatment. Conclusion Allergic reactions are common with OXA, which can lead to the interruption of chemotherapy. Severe allergy even poses a threat to patients' safety. The clinical medical staff should be alert to the allergic reactions of OXA, strengthen monitoring and prevention, and improve the safety of medication for patients.

Key words: oxaliplatin, ADR, allergic reactions, drug safety

中图分类号:

R994.11

李敏, 钟巧妮, 赵丽, 兰露露, 刘东, 张程亮. 中国患者奥沙利铂过敏反应文献分析[J]. 中国药物警戒, 2020, 17(11): 798-802.

LI Min, ZHONG Qiaoni, ZHAO Li, LAN Lulu, LIU Dong, ZHANG Chengliang. Literature analysis of Oxaliplatin Allergic Reactions in Chinese patients[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 798-802.

参考文献

[1] Wang H, Xu L, Zhao L, et al.Literature Analysis of 126 Cases of Adverse Drug Reactions Induced by Oxaliplatin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 110-114.
[2] Georg Lenz, Ulrich T. Hacker,Wolfgang Kern., et al.Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution[J].Anti-cancer Drug, 2003, 14(9):731-733.
[3] MaindraultGoebel F, André T, Tournigand C,et al.Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients[J]. Eur J Cancer, 2005, 41(15): 2262-2267.
[4] Ichikawa Y, Goto A, Hirokawa S,et al.Allergic Reactions to Oxaliplatin in a Single Institute in Japan[J].Jpn J Clin Oncol, 2009, 39(9): 616-620.
[5] Song QY,Li T.Oxaliplatin induced anaphylaxis in 1 patient[J]. China Practical Medicine(中国实用医药), 2014, 9(3):195-196.
[6] Li HH.Anaphylaxis induced by oxaliplatin for injection in 1 case[J]. China Medical Herald(中国医药导报), 2011, 8(13): 130.
[7] Basketter D A, McFadden J P, Kimber I.Assessing the severity of allergic reactions: a regulatory dilemma[J].Contact Dermatitis, 2012, 67(1): 3-8.
[8] Mori Y, Nishimura T, Kitano T,et al.Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX[J].Oncology, 2010, 79(1-2): 136-143.
[9] Siu SWK, Chan RTT, Au GKH.Hypersensitivity reactions to oxaliplatin: experience in a single institute[J]. Official Journal of the European Society for Medical Oncology, 2006, 17(2): 259-261.
[10] Micheli L, Mattoli L, Maidecchi A,et al.Effect of Vitis vinifera hydroalcoholic extract against oxaliplatin neurotoxicity: in vitro and in vivo evidence[J].Sci Rep, 2018, 8(1): 14364.
[11] Lee K, Park Y J, Kim E S,et al.Hypersensitivity Reactions to Oxaliplatin[J].Cancer Res Treat, 2006, 38(4): 240-241.
[12] Kim BH, Bradley T, Tai J,et al.Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review[J].Oncology, 2009, 76(4): 231-238.
[13] Zeng PH, Shu LL, Xie XH, et al.Comparative analysis of clinical and endoscopic data of colorectal cancer patients of different ages[J].The New Med, 2005(8): 451-453.
[14] Zhao B, Zhong HG,Gao F, et al.Epidemiological analysis of 3720 cases of colorectal cancer in Guangxi[J].Guangdong Medical, 2013, 34(14): 2239-2242.
[15] Rogers BB, Cuddahy T, Briscella C,et al.Oxaliplatin: Detection and Management of Hypersensitivity Reactions[J].Clin J Oncol Nurs, 2019, 23(1): 68-75.
[16] Brandi G, Pantaleo M A, Galli C,et al.Hypersensitivity reactions related to oxaliplatin (OHP)[J].Brit J Cancer, 2003, 89(3): 477-481.
[17] Castells MCMP, Tennant NMB, Sloane DEM,et al.Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensi-tization in 413 cases[J].J of Allerg and Clin Immunol, 2008, 122(3): 574-580.
[18] Zhang X, Zhao Y, Dong Y.The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions[J].J Investig Allergol Clin Immunol, 2017, 27(1): 65-66.
[19] Li Xiaotong,Zhai Suodi,Wang Qiang,et al.First aid guide for severe allergic reactions[J].Adverse Drug Reactions Journal, 2019, 21(2): 85-91.
[20] Parel M, Ranchon F, Nosbaum A, et al.Hypersensitivity to oxaliplatin: clinical features and risk factors[J].Bmc Pharmacol Toxicol, 2014, 15: 1.
[21] Xu Y, Chen L, Zhu H, et al.Rationality and Safety of Oxaliplatin Prescription[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2016,13(3):176-179.
[22] Waddle M, Irvin M, Gupta E,et al.Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion[J].Chemother, 2017, 62(5): 295-300.
[23] Lai J, Wang W.Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review[J].Pharmacy World & Science, 2009, 31(5): 538-541.
[24] Garciaz S, Oziel-Taieb S, Dermeche S,et al.Acute immune hematological complication of oxaliplatin. A series of 3 cases[J]. Tumori, 2014, 100(1): 17-19.
[25] Yamauchi H, Goto T, Takayoshi K,et al.A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin[J].Eur J Cancer Care, 2015, 24(1): 111-116.
[26] Nishihara M, Nishikura K, Morikawa N,et al.Factors Influencing the Appearance of Oxaliplatin-Induced Allergy[J].Biol Pharm Bull, 2017, 40(12): 2105-2109.
[27] Bonadonna MPP.Skin Test Protocol for the Prevention of Hypers-ensitivity Reactions to Oxaliplatin[J].Anti-cancer Res, 2014, 34: 537-540.
[28] Nozawa HMP, Muto YMP, Yamada YMP.Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer[J].Clin Ther, 2008, 30(6): 1160-1165.
[29] Rose PG, Metz C, Link N.Desensitization With Oxaliplatin in Patients Intolerant of Carboplatin Desensitization[J].Intern J of Gynecol Cancer, 2014, 24(9): 1603-1606.
[30] Takako Y, Iwasa S, Hashimoto H.Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer[J].Anti-cancer Res, 2012, 32: 5521-5526.
[31] Lydia Mis,Nishan HF,Hurbert IH,et al.Successful Desens-itization to Oxaliplatin[J].The Annals of Pharmacotherapy, 2005, 39: 966-969.

中国患者奥沙利铂过敏反应文献分析

Literature analysis of Oxaliplatin Allergic Reactions in Chinese patients

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[7]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[8]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.